Biological Activity Mechanism of action side effects
ChemicalBook > CAS DataBase List > Crizotinib

Crizotinib

Biological Activity Mechanism of action side effects
Crizotinib Structure
Crizotinib
  • CAS No.877399-52-5
  • Chemical Name:Crizotinib
  • CBNumber:CB12473904
  • Molecular Formula:C21H22Cl2FN5O
  • Formula Weight:450.343
  • MOL File:877399-52-5.mol
Crizotinib Property
  • Melting point: :192 °C
  • Boiling point: :599.2±50.0 °C(Predicted)
  • Density  :1.47±0.1 g/cm3(Predicted)
  • storage temp.  :room temp
  • pka :9.81±0.10(Predicted)
  • form  :powder
  • color  :white to tan
  • CAS DataBase Reference :877399-52-5
  • FDA UNII :53AH36668S
  • NCI Dictionary of Cancer Terms :crizotinib; Xalkori
Safety
  • Safety Statements  :24/25
  • RIDADR  :UN 3077 9 / PGIII
  • WGK Germany  :3
  • HazardClass  :IRRITANT
  • HS Code  :29333990
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordWarning
  • Hazard statements H317-H319-H341-H400
  • Precautionary statements P273-P280-P305+P351+P338
Crizotinib Price More Price(3)
  • Brand: Cayman Chemical
  • Product number: 12087
  • Product name : Crizotinib
  • Purity: ≥98%
  • Packaging: 5mg
  • Price: $95
  • Updated: 2020/06/24
  • Buy: Buy
  • Brand: Cayman Chemical
  • Product number: 12087
  • Product name : Crizotinib
  • Purity: ≥98%
  • Packaging: 10mg
  • Price: $165
  • Updated: 2020/06/24
  • Buy: Buy
  • Brand: Cayman Chemical
  • Product number: 12087
  • Product name : Crizotinib
  • Purity: ≥98%
  • Packaging: 50mg
  • Price: $550
  • Updated: 2020/06/24
  • Buy: Buy

Crizotinib Chemical Properties,Usage,Production

  • Biological Activity Potent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50 values are 8.0 and 20 nM respectively). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable.
  • Mechanism of action Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d’Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in the activation and dysregulation of the gene's expression and signaling, which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrates concentration-dependent inhibition of ALK and c-Met phosphorylation in cell-based assays using tumor cell lines, and also demonstrates antitumor activity in mice bearing tumor xenografts that express EML4-or NPM-ALK fusion proteins or c-Met.Crizotinib is a multitargeted small molecule tyrosine kinase inhibitor, which had been originally developed as an inhibitor of the mesenchymal epithelial transition growth factor (c-MET); it is also a potent inhibitor of ALK phosphorylation and signal transduction. This inhibition is associated with G1-S phase cell cycle arrest and induction of apoptosis in positive cells in vitro and in vivo. Crizotinib also inhibits the related ROS1 receptor tyrosine kinase.
    References
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876666/
  • side effects crizotinib (Xalkori) is an oral receptor tyrosine kinase inhibitor indicated for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). Common side effects with Xalkori use include upper respiratory infection, nausea, vomiting, stomach pain, decreased appetite, insomnia, dizziness, tired feeling, diarrhea, constipation, rash or itching, cold symptoms (stuffy nose, sneezing, sore throat), numbness or tingling, or swelling in your hands or feet.
    http://www.rxlist.com/xalkori-side-effects-drug-center.htm
  • Description In August 2011, the United States FDA approved crizotinib (PF- 02341066) for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC). Crizotinib is a dual ATP competitive inhibitor of tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50=8 nM) and ALK (cellular IC50=20 nM), both of which are important targets for cancer chemotherapy. When crizotinib was tested for selectivity versus other kinases it was found to have enzyme IC50's within 100-fold multiples of c-MET for 13 of the 120 kinases tested. In cellular assays, crizotinib was found to inhibit RON (recepteur d’origine nantais) kinase with a 10-fold selectivity window over c-MET.
  • Chemical Properties White Solid
  • Originator Pfizer (United States)
  • Uses A potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). A potential antitumor agent.
  • Uses Crizotinib is a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Crizotinib is a potential antitumor agent.
  • Uses PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley
  • Definition ChEBI: A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients wi h locally advanced or metastatic non-small cell lung cancer (NSCLC)
  • Indications Crizotinib (Xalkori(R), Pfizer), approved in 2011, was the first approved inhibitor targeting anaplastic lymphoma kinase (ALK). ROS protooncogene 1-encoded kinase (ROS1) of the tyrosine kinase insulin receptor class and MET proto-oncogene-encoded kinase of the hepatocyte growth factor receptor (HGFR) class are other kinases targeted by crizotinib.When approved in 2011, crizotinib was the first drug specifically targeting NSCLC patients. However, resistance to crizotinib was usually observed in approximately 8 months after initial application and more than half of crizotinib-treated patients experienced gastrointestinal side effects. In 2016,crizotinib was additionally approved for ROS1-positive NSCLC by FDA.
  • brand name Xalkori
Crizotinib Preparation Products And Raw materials
Raw materials
Preparation Products
Global(370)Suppliers
  • Supplier:
    TianYuan Pharmaceutical CO.,LTD
  • Tel:+86-755-23284190 13684996853
  • Fax:+86-755-23284190
  • Email:sales@tianpharm.com
  • Country:CHINA
  • ProdList:305
  • Advantage:58
  • Supplier:
    Capot Chemical Co.,Ltd.
  • Tel:+86(0)13336195806 +86-571-85586718
  • Fax:+86-571-85864795
  • Email:sales@capotchem.com
  • Country:China
  • ProdList:19931
  • Advantage:60
  • Supplier:
    Henan Tianfu Chemical Co.,Ltd.
  • Tel:0371-55170693
  • Fax:0371-55170693
  • Email:info@tianfuchem.com
  • Country:CHINA
  • ProdList:22623
  • Advantage:55
  • Supplier:
    Hangzhou FandaChem Co.,Ltd.
  • Tel:0086 158 5814 5714 (Mobile
  • Fax:+86-571-56059825
  • Email:fandachem@gmail.com
  • Country:CHINA
  • ProdList:3292
  • Advantage:55
Related articles
877399-52-5, CrizotinibRelated Search:
  • 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-2-aMinopyridine
  • (R)-3-[1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylaMine
  • [3-[[(R)-1-(2,6-Dichloro-3- fluorophenyl)ethyl]oxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-yl]aMine
  • 2-PyridinaMine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-
  • Crozotinib
  • Crizotinib,PF-02341066
  • Xalkori
  • Crizotinib Xalkori
  • 3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-[1-(PIPERIDIN-4-YL)-1H-PYRAZOL-4-YL]PYRIDIN-2-AMINE
  • 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
  • (R)-Crizotinib
  • PF 2341066; PF2341066
  • CS-164
  • PF 02341066 - Crizotinib | PF 2341066
  • Crizotinib ? ?3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
  • Crizotinib (PF2341066)
  • PF-02341066 Crizotinib
  • 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
  • k-ras(g12c) inhibitor 6 NA Crizotinib
  • Crizotinib, >=98%
  • 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridin
  • 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-Pyridinamine
  • (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
  • 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]pyridin-2-amine
  • Crizotinib
  • PF 2341066
  • PF-02341066
  • PF-2341066/Crizotinib
  • 3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine
  • 877399-52-5
  • 877395-52-5
  • 87399-52-5
  • 77399-52-5
  • 877399-52-6
  • C21H22Cl2FN5O
  • API
  • API
  • Inhibitor
  • Aromatic
  • Chiral Reagents
  • Heterocycles
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pfizer Compounds
  • Pharmaceuticals
  • Anti-cancer & immunity